The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Open accessAbstract
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages the nigrostriatal dopaminergic pathway as seen in Parkinson's disease (PD), a common neurodegenerative disorder with no effective protective treatment. Consistent with a role of glial cells in PD neurodegeneration, here we show that minocycline, an approved tetracycline derivative that inhibits microglial activation independently of its antimicrobial properties, mitigates both the demise of nigrostriatal dopaminergic neurons and the formation of nitrotyrosine produced by MPTP. In addition, we show that minocycline not only prevents MPTP-induced activation of microglia but also the formation of mature interleukin-1beta and the activation of NADPH-oxidase and inducible nitric oxide synthase (iNOS), three key microglial-derived cytotoxic mediators. Previously, we demonstrated that ablation of iNOS attenuates MPTP-induced neurotoxicity. Now, we demonstrate that iNOS is not the only microglial-related culprit implicated in MPTP-induced toxicity because mutant iNOS-deficient mice treated with minocycline are more resistant to this neurotoxin than iNOS-deficient mice not treated with minocycline. This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This effect is mainly ascribable to the minocycline-dependent suppression of microglia activation, which has been reported by several in vivo studies [251,258,259,260,261,262,263].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
In the citing paper
“In this respect, microglial inactivation by minocycline correlates with decreased IL-1β formation, as well as reduced NADPH-oxidase and inducible nitric oxide synthase (iNOS) activity, suggesting that both anti-inflammatory and antioxidant pathways are involved [262,264].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
In the citing paper
“In this respect, microglial inactivation by minocycline correlates with decreased IL-1β formation, as well as reduced NADPH-oxidase and inducible nitric oxide synthase (iNOS) activity, suggesting that both anti-inflammatory and antioxidant pathways are involved [262,264].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
In the citing paper
“In this respect, microglial inactivation by minocycline correlates with decreased IL-1β formation, as well as reduced NADPH-oxidase and inducible nitric oxide synthase (iNOS) activity, suggesting that both anti-inflammatory and antioxidant pathways are involved [262,264].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [262]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals in biology and medicine
Gutteridge, J. M. C. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
Free Radicals in Biology and Medicine
Land, E. J. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,871
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Microglia: Intrinsic immuneffector cell of the brain
Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 19×
“…decreases MPTP-mediated nitrotyrosine formation A significant part of the MPTP neurotoxic process is mediated by NO-related oxidative damage (Przedborski et al., 2000), the extent of which can be evaluated by assessing nitrotyrosine levels (Liberatore et al., 1999; Pennathur et al., 1999).”
BackgroundMethodResultInfluentialYrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993) · Glia · doi:10.1002/glia.440070117 · Cited by 1,032
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Research works printed but not linked: 1
- Fahn S, Przedborski S (2000) Parkinsonism. In: Merritt's neurology (Rowland LP, ed), pp 679 -693. New York: Lippincott Williams & Wilkins.
Cited by
Sorted by citations
Items 701–800 of 999
IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP
Nadjar, A., Berton, O., Guo, S., Leneuve, P., Doveró, S., Diguet, E., Tison, F., Zhao, B., Holzenberger, M., & Bézard, E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.02.009 · Cited by 41
Stolp, H. B., Ek, C. J., Johansson, P. A., Dzięgielewska, K. M., Potter, A., Habgood, M. D., & Saunders, N. R. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05973.x · Cited by 39
(Re)building the nervous system: A review of neuron–glia interactions from development to disease
Demmings, M. D., Chagas, L. D. S., Traetta, M. E., Rodrigues, R. S., Acutain, M. F., Barykin, E. P., Datusalia, A. K., German‐Castelan, L., Mattera, V. S., Mazengenya, P., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16258 · Cited by 44
Manivasagam, T., Nataraj, J., Tamilselvam, K., Essa, M., & Janakiraman, U. (2013) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/2231-0738.114875 · Cited by 38
Systemic Inflammation in Lewy Body Diseases
King, E., & Thomas, A. J. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000211 · Cited by 38
Burks, S. M., Raymick, J. B., Robinson, B. L., Hanig, J. P., & Sarkar, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.03.015 · Cited by 38
Biomarkers and the Role of α-Synuclein in Parkinson’s Disease
Du, T., Wang, L., Liu, W., Zhu, G., Chen, Y., & Zhang, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.645996 · Cited by 41
Microglial IL-10 and β-endorphin expression mediates gabapentinoids antineuropathic pain
Ahmad, K. A., Shoaib, R. M., Ahsan, M. Z., Deng, M.-Y., Ma, L., Apryani, E., Li, X., & Wang, Y. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.04.007 · Cited by 38
Fakhri, S., Piri, S., Moradi, S. Z., & Khan, H. Z. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210809103346 · Cited by 39
Extracellular alpha-synuclein: Sensors, receptors, and responses
Domingues, R., Sant’Anna, R., da Fonseca, A. C. C., Robbs, B. K., Foguel, D., & Outeiro, T. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105696 · Cited by 38
Renin angiotensin system and gender differences in dopaminergic degeneration
Rodriguez-Perez, A. I., Valenzuela, R., Joglar, B., Garrido‐Gil, P., Guerra, M. J., & Labandeira-García, J. L. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-58 · Cited by 38
New developments of brain imaging for Parkinson's disease and related disorders
Piccini, P., & Brooks, D. J. (2006) · Movement Disorders · doi:10.1002/mds.20845 · Cited by 100
Accelerated Aging during Chronic Oxidative Stress: A Role for PARP-1
Boesten, D. M. P. H. J., de Vos-Houben, J. M. J., Timmermans, L., den Hartog, G. J. M., Bast, A., & Hageman, G. J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/680414 · Cited by 37
Kumar, V., Singh, B. K., Chauhan, A. K., Singh, D., Patel, D. K., & Singh, C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9137-y · Cited by 37
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R., Rahman, H., Behl, T., Chowdhury, M. A. R., Manirujjaman, M., Bulbul, I. J., Elshenawy, S. E., Ţiţ, D. M., & BUNGAU, S. G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210218084444 · Cited by 40
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 38
Wiley, N. J., Madhankumar, A. B., Mitchell, R. M., Neely, E. B., Rizk, E., Douds, G. L., Simmons, Z., & Connor, J. R. (2012) · Advances in Nanoparticles · doi:10.4236/anp.2012.13007 · Cited by 37
Seo, M., Kim, S., Kim, S., Zheng, L. T., Park, E. K., Lee, W., & Suk, K. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21552 · Cited by 40
Xing, B., Xin, T., Zhao, L., Hunter, R. L., Chen, Y., & Bing, G. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.04.010 · Cited by 37
Zhao, Q. S., Cai, D., & Bai, Y. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1450 · Cited by 37
α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
Butkovich, L. M., Houser, M. C., & Tansey, M. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00626 · Cited by 39
SIRT1 activation by minocycline on regulation of microglial polarization homeostasis
Wu, L.-H., Huang, B., Lai, S., Lin, C., Lin, H., Yang, L., & Lu, D. (2020) · Aging · doi:10.18632/aging.103542 · Cited by 37
Minocycline delayed photoreceptor death in rds mice through iNOS-dependent mechanism.
Yang, L.-P., Li, Y., Zhu, X. A., & Tso, M. O. M. (2007) · PubMed Central · Cited by 37
Shih, Y., Chen, I., Wu, Y., & Lo, Y. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep025 · Cited by 37
Kawasaki, T., Ishihara, K., Ago, Y., Baba, A., & Matsuda, T. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.119206 · Cited by 37
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Lian, Q., Dheen, S. T., Liao, D., & Tay, S. S. W. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20006 · Cited by 36
Madathil, K. S., Karuppagounder, S. S., Haobam, R., Varghese, M., Rajamma, U., & Mohanakumar, K. P. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.007 · Cited by 36
The effect of α-synuclein on gliosis and IL-1α, TNFα, IFNγ, TGFβ expression in murine brain
Sznejder-Pachołek, A., Joniec‐Maciejak, I., Wawer, A., Ciesielska, A., & Mirowska-Guzel, D. M. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.11.003 · Cited by 36
Long-term Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson’s Disease
Huang, D., Wang, Z., Tong, J., Wang, M., Wang, J., Xu, J., Bai, X., Li, H., Huang, Y., Wu, Y., et al. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.11.041 · Cited by 36
El-Sayed, E. K., Ahmed, A., Morsy, E. M. E., & Nofal, S. (2018) · Human & Experimental Toxicology · doi:10.1177/0960327118788139 · Cited by 36
Lecours, C., St‐Pierre, M., Picard, K., Bordeleau, M., Bourque, M., Awogbindin, I. O., Benadjal, A., Ibáñez, F. G., Gagnon, D., Cantin, L., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.044 · Cited by 34
López, I. A., Acuña, D., Beltrán‐Parrazal, L., Lopez, I. E., Amarnani, A., Cortes, M., & Edmond, J. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-53 · Cited by 35
Gene Deletion of nos2 Protects Against Manganese-Induced Neurological Dysfunction in Juvenile Mice
Streifel, K. M., Moreno, J. A., Hanneman, W. H., Legare, M. E., & Tjalkens, R. B. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr335 · Cited by 36
Costunolide inhibits proinflammatory cytokines and iNOS in activated murine BV2 microglia
Dheen, S. T. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e312 · Cited by 36
He, X., Uchida, K., Megumi, C., Tsuge, N., & Nakayama, H. (2015) · Journal of Toxicologic Pathology · doi:10.1293/tox.2015-0020 · Cited by 34
Inamdar, A. A., Chaudhuri, A., & O’Donnell, J. M. (2012) · Parkinson s Disease · doi:10.1155/2012/938528 · Cited by 35
Han, Y.-Y., Jin, K., Pan, Q.-S., Li, B., Wu, Z.-Q., Gan, L., Yang, L., & Long, C. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.011 · Cited by 35
Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction
Mancini, A., Ghiglieri, V., Parnetti, L., Calabresi, P., & Filippo, M. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.644294 · Cited by 38
Yokoyama, H., Yano, R., Kuroiwa, H., Tsukada, T., Uchida, H., Kato, H., Kasahara, J., & Araki, T. (2010) · Metabolic Brain Disease · doi:10.1007/s11011-010-9191-0 · Cited by 35
Majde, J. A. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.02.023 · Cited by 36
Oxidative stress and microglial activation in substantia nigra following striatal MPP+
Miwa, H., Kubo, T., Morita, S., Nakanishi, I., & Kondo, T. (2004) · Neuroreport · doi:10.1097/00001756-200404290-00021 · Cited by 35
Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease
Diguet, E., Rouland, R., & Tison, F. (2003) · Annals of Neurology · doi:10.1002/ana.10818 · Cited by 35
Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment
Diguet, E., Gross, C. E., Bézard, E., Tison, F., Stefanova, N., & Wenning, G. K. (2004) · Neurology · doi:10.1212/wnl.62.1.158 · Cited by 35
Minocycline Markedly Reduces Acute Visceral Nociception via Inhibiting Neuronal ERK Phosphorylation
Cho, I., Lee, M. J., Jang, M., Gwak, N.-G., Lee, K. Y., & Jung, H. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-13 · Cited by 34
Effect of resveratrol and tetracycline on the subacute paraquat toxicity in mice
Satpute, R. M., Pawar, P., Puttewar, S., Sawale, S., & Ambhore, P. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327116688070 · Cited by 34
Mariucci, G., Pagiotti, R., Galli, F., Romani, L. R., & Conte, C. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1057-7 · Cited by 34
The Role of Neuroinflammation in Neurodegenerative Disorders
Suescun, J., Chandra, S., & Schiess, M. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00013-3 · Cited by 34
Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines
Park, C., Kim, S., & Lee, C. (2020) · Immune Network · doi:10.4110/in.2020.20.e47 · Cited by 34
Frau, L., Borsini, F., Wardas, J., Khairnar, A., Schintu, N., & Morelli, M. (2010) · Synapse · doi:10.1002/syn.20833 · Cited by 34
Microglial Ion Channels as Potential Targets for Neuroprotection in Parkinson’s Disease
Richardson, J. R., & Hossain, M. M. (2013) · Neural Plasticity · doi:10.1155/2013/587418 · Cited by 33
Cellular Models to Study Dopaminergic Injury Responses
Collier, T. J., Steece‐Collier, K., McGuire, S. O., & Sortwell, C. E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07472.x · Cited by 34
Lu, Y., Lei, S., Wang, N., Lu, P., Li, W., Zheng, J., Giri, P. K., Lü, H., Chen, X., Zuo, Z., et al. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00135 · Cited by 34
Cho, K.-I., Searle, K. M., Webb, M., Yi, H., & Ferreira, P. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1071-9 · Cited by 33
Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies
Fernagut, P., Dehay, B., Maillard, A., Bézard, E., Perez, P., Traon, A. P., Rascol, O., Foubert‐Samier, A., Tison, F., & Meissner, W. G. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.021 · Cited by 35
Current Development of Acupuncture Research in Parkinson's Disease
Zeng, B., Salvage, S., & Jenner, P. G. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411545-3.00007-9 · Cited by 32
Oda, W., Fujita, Y., Baba, K., Mochizuki, H., Niwa, H., & Yamashita, T. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03469-2 · Cited by 33
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Rabaneda‐Lombarte, N., Serratosa, J., Bové, J., Vila, M., Saura, J., & Solà, C. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02132-z · Cited by 33
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Kato, H. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00411-2 · Cited by 33
Iravani, M. M., Sadeghian, M., Leung, C. C. M., Tel, B. C., Rose, S., Schapira, A. H. V., & Jenner, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.04.037 · Cited by 32
Henze, C., Hartmann, A., Lescot, T., Hirsch, É. C., & Michel, P. P. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03416.x · Cited by 33
Hasbani, D. M., Perez, F. A., Palmiter, R. D., & O’Malley, K. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0130-05.2005 · Cited by 33
Bhandare, A., Kapoor, K., Powell, K. L., Braine, E. L., Casillas-Espinosa, P. M., O'Brien, T. J., Farnham, M. M. J., & Pilowsky, P. M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.012 · Cited by 32
Are immunotherapies for Huntington’s disease a realistic option?
Denis, H. L., Lauruol, F., & Cicchetti, F. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0021-9 · Cited by 32
Kalampokini, S., Becker, A., Fassbender, K. C., Lyros, E., & Unger, M. M. (2019) · Parkinson s Disease · doi:10.1155/2019/7535472 · Cited by 34
Shwe, T., Bo‐Htay, C., Ongnok, B., Chunchai, T., Jaiwongkam, T., Kerdphoo, S., Kumfu, S., Pratchayasakul, W., Pattarasakulchai, T., Chattipakorn, N., et al. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111465 · Cited by 32
The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies
Rivers‐Auty, J., & Ashton, J. C. (2010) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152410790780145 · Cited by 32
Kremlev, S. G., Roberts, R. L., & Palmer, C. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21380 · Cited by 33
Boger, H. A., Middaugh, L. D., Zaman, V., Hoffer, B. J., & Granholm, A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.09.011 · Cited by 32
Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death
Fernández-Gómez, F.-J., Gómez-Lázaro, M., Pastor, M. D., Calvo, S., Aguirre, N., Galindo, M. F., & Jordán, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.019 · Cited by 32
MacGillivray, L., Reynolds, K. B., Sickand, M., Rosebush, P. I., & Mazurek, M. F. (2011) · Synapse · doi:10.1002/syn.20954 · Cited by 32
Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Gargiulo, S., Gamba, P., Poli, G., & Leonarduzzi, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660701 · Cited by 34
Tactics for Vascular Protection After Acute Ischemic Stroke
Fagan, S. C., Hess, D. C., Machado, L. S., Hohnadel, E. J., Pollock, D. M., & Ergul, A. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.3.387.59293 · Cited by 32
Chen, L.-W., Hu, H., Liu, L., Yung, K. K. L., & Chan, Y. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.020 · Cited by 31
Li, D., Song, X., Huang, H., Huang, H., & Ye, Z. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.027 · Cited by 31
Yuan, Z., Chen, X., Yang, W., Lou, B., Ye, N., & Liu, Y. (2019) · PubMed Central · Cited by 31
Neuroprotective and toxic changes in microglia in neurodegenerative disease
Sawada, M. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70011-2 · Cited by 30
More, S. V., Kumar, H., Kim, I., Koppula, S., Kim, B.-W., & Choi, D. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990059 · Cited by 31
Kavanagh, E. T., Burguillos, M. Á., Carrillo-Jiménez, A., Oliva-Martín, M. J., Santiago, M., Rodhe, J., Joseph, B., & Venero, J. L. (2015) · Aging · doi:10.18632/aging.100805 · Cited by 30
Retardation of Brain Aging by Chronic Treatment with Melatonin
Bondy, S. C., Lahiri, D. K., Perreau, V. M., Sharman, K., Campbell, A., Zhou, J., & Sharman, E. H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.013 · Cited by 31
Roles of Microglia in Neurodegenerative Diseases
Nakaso, K. (2024) · Yonago acta medica · doi:10.33160/yam.2024.02.001 · Cited by 30
Stroke and immunotherapy: Potential mechanisms and its implications as immune‐therapeutics
Chavda, V. K., Madhwani, K., & Chaurasia, B. K. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15224 · Cited by 30
GCH1 Deficiency Activates Brain Innate Immune Response and Impairs Tyrosine Hydroxylase Homeostasis
Larbalestier, H., Keatinge, M., Watson, L., White, E., Gowda, S. B., Wei, W., Koler, K., Semenova, S. A., Elkin, A. M., Rimmer, N., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0653-21.2021 · Cited by 30
Novel therapeutic approaches to target neurodegeneration
de la Fuente, A. G., Pelucchi, S., Mertens, J., Luca, M. D., Mauceri, D., & Marcello, E. E. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16078 · Cited by 32
Oxidative Stress, Neuroinflammation, and Neurodegeneration
Gao, H., Zhou, H., & Hong, J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1071-7_5 · Cited by 30
Stefanova, N., Mitschnigg, M., Ghorayeb, I., Diguet, E., Geser, F., Tison, F., Poewe, W. H., & Wenning, G. K. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20233 · Cited by 30
Metabolic Enhancement of the Soldier Brain
Friedl, K. E., & Grate, S. J. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780190455132.003.0002 · Cited by 29
Čížková, D., Devaux, S., Marrec‐Croq, F. L., Franck, J., Slovinská, L., Blaško, J., Rosocha, J., Špaková, T., Lefebvre, C., Fournier, I., et al. (2014) · Scientific Reports · doi:10.1038/srep07514 · Cited by 32
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γAgonist against MPTP
Swanson, C. R., Du, E. Y., Johnson, D. A., Johnson, J. A., & Emborg, M. E. (2013) · PPAR Research · doi:10.1155/2013/582809 · Cited by 29
Zhu, X., Yao, Y., Yang, J., Ge, Q., Niu, D., Liu, X., Zhang, C., Gan, G., Zhang, A., & Yao, H. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108044 · Cited by 29
Kouroupi, G., Antoniou, N., Prodromidou, K., Taoufik, E., & Matsas, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197113 · Cited by 30
Importance of the Brain Angiotensin System in Parkinson’s Disease
Wright, J. W., & Harding, J. W. (2012) · Parkinson s Disease · doi:10.1155/2012/860923 · Cited by 30
Emerging chemotherapeutic strategies for Huntington’s disease
Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 30
Reddy, P. V. B., Rao, K. V. R., & Norenberg, M. D. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22097 · Cited by 28
Rotenone-induced neurotoxicity in rat brain areas: A study on neuronal and neuronal supportive cells
Swarnkar, S., Goswami, P., Kamat, P., Patro, I. K., Singh, S. P., & Nath, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.10.034 · Cited by 28
Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline
Cornet, S., Spinnewyn, B., Delaflotte, S., Charnet, C., Roubert, V., Favre, C., Hider, H., Chabrier, P. E., & Auguet, M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.039 · Cited by 28
Yu, J., Wang, J., Cadet, J. L., & Angulo, J. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.077 · Cited by 28
Michel-Monigadon, D., Nerrière‐Daguin, V., Lévêque, X. T., Plat, M., Venturi, É., Brachet, P., Naveilhan, P., & Neveu, I. (2010) · Transplantation · doi:10.1097/tp.0b013e3181cbe041 · Cited by 27
Metadata
- Authors
- Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S.
- Affiliations
- Pediatrics and Genetics (US)
- Children's Hospital of Philadelphia (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2002-03-01
- Volume
- 22
- Issue
- 5
- Pages
- 1763-1771
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6758858
- OpenAlex
- W2148726772
- Cited by
- 1,183
- References
- 44
- Citations by year
- 2026: 13 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 27 · 2021: 41 · 2020: 27 · 2019: 40 · 2018: 47 · 2017: 42 · 2016: 43 · 2015: 43 · 2014: 68 · 2013: 69 · 2012: 63
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- Parkinson's Disease Foundation (NS38370)
- Muscular Dystrophy Association
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5r29ns037345-05, NS38370)
- National Institute on Aging (R01-AG13966, R01AG013966)
- National Institute of Neurological Disorders and Stroke (P50-NS38370, R01 NS 38586, R01 NS 42269, R29 NS37345, R01NS042269, R01NS038586, P50NS038370)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, microglial activation, minocycline, MPTP-induced neurotoxicity, neuroprotection, nitrotyrosine, IL-1β, NADPH oxidase, inducible nitric oxide synthase, nigrostriatal dopaminergic neurons, neuroinflammation, iNOS-deficient mice
- MeSH terms
- Animals, Anti-Bacterial Agents, Astrocytes, Corpus Striatum, Disease Models, Animal, Dose-Response Relationship, Drug, Interleukin-1, Mice, Inbred C57BL, Minocycline, Neurons, Substantia Nigra, Tyrosine, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Up-Regulation, Microglia, Mice, Knockout, Neuroprotective Agents, Nitric Oxide Synthase, NADPH Oxidases, Parkinsonian Disorders, Mice, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
